Pertussis, commonly known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It poses significant health risks, particularly to infants and young children. The resurgence of pertussis in many countries has led to calls for an improved vaccine.
Using its patented innovative technology, BioNet is leading the development and manufacturing of next-generation pertussis vaccines.
BioNet’s recombinant acellular pertussis vaccine is unique in that it contains a genetically inactivated pertussis toxin (PTgen), a component found in all acellular pertussis vaccines.
PTgen has been extensively evaluated in clinical trials involving children and adults.
BioNet’s recombinant pertussis vaccine is licensed in Asia as Pertagen®, and applications for licensure under different names have been submitted in other regions.
Pertagen®
This monovalent recombinant pertussis vaccine contains a genetically detoxified pertussis toxin (PTgen). It has been specifically designed to boost immunity against pertussis.
An innovative way to prevent pertussis
Current acellular pertussis vaccines are combined with other vaccines. It may be beneficial to have access to a vaccine that targets a specific disease, when vaccination against other diseases is not recommended.
Through this novel vaccine targeting pertussis only, BioNet can provide an innovative solution to manage pertussis vaccination during pregnancy.
BioNet has been expanding its portfolio of pertussis-containing vaccines with more presentations including combination vaccines. Combined trivalent vaccines containing diphtheria, tetanus and recombinant acellular pertussis vaccines have also been licensed in Asia and other regions using different formulations.
Clinical Trials
The safety, immunogenicity and antibody persistence of BioNet pertussis vaccines have been demonstrated in clinical trials in different populations.
Adolescent
5-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Read more >
A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined tetanus-diphtheria-acellular Pertussis vaccine as compared to Adacel® vaccine in healthy subjects aged 12-17 years
Read more >
A phase II randomized, observer-blind controlled pilot study to compare the safety and immunogenicity of acellular pertussis vaccines including chemically or genetically-detoxified pertussis toxin in adolescents aged 11-15 years previously immunized with acellular pertussis vaccines
Read more >
Adults
An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-30 years
Read more >
Safety and antibody responses in adults and elderly after immunization with a recombinant pertussis booster dose
Read more >
Pregnant women
Antibody level in cord sera following immunization with recombinant acellular pertussis vaccines during pregnancy: a prospective, observational study
Read more >
A phase II randomized, observer-blind, active-controlled study to evaluate the immunogenicity and the safety of BioNet recombinant pertussis vaccines with different doses of genetically detoxified pertussis toxin (PTgen) when administered to healthy pregnant women
Read more >
Disclaimer: The trademarks Pertagen® and Boostagen® are owned by BioNet and are used in accordance with applicable trademark laws. Availability of these products may vary by country and is subject to local regulatory approval. The information provided on this webpage is intended for informational purposes only and should not be considered as medical advice or a substitute for professional healthcare consultation.